补肺消积汤联合AP化疗方案治疗晚期非小细胞肺癌患者的效果

Effects of Bufei Xiaoji decoction combined with AP chemotherapy in treatment of patients with advanced non-small cell lung cancer

目的:观察补肺消积汤联合AP化疗方案(培美曲塞+顺铂)治疗晚期非小细胞肺癌(NSCLC)患者的效果。方法:选取2020年9月至2023年9月该院收治的86例晚期NSCLC患者进行前瞻性研究,按照随机数字表法将其分为研究组与对照组各43例,对照组采用AP化疗方案治疗,研究组在对照组基础上联用补肺消积汤治疗。比较两组临床疗效,治疗前后肿瘤标志物[细胞角蛋白21-1片段(CYFRA21-1)、癌胚抗原(CEA)]水平、生命质量[肺癌患者生存质量测定量表(FACT-L)]评分,以及不良反应发生率。结果:研究组疾病控制率为95.35%(41/43),高于对照组的79.01%(34/43),差异有统计学意义(P<0.05);治疗后,两组CYFRA21-1、CEA水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组FACT-L评分均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:补肺消积汤联合AP化疗方案用于晚期NSCLC患者可提高疾病控制率和生命质量,降低肿瘤标志物水平,安全性良好,效果优于单用AP化疗方案。

Objective:To observe effects of Bufei Xiaoji decoction combined with AP chemotherapy regimen(Pemetrexed+Cisplatin)in treatment of patients with advanced non-small cell lung cancer(NSCLC).Methods:A prospective study was conducted on 86 patients with advanced NSCLC admitted to this hospital from September 2020 to September 2023.According to the random number table method,they were divided into study group and control group,43 cases in each group.The control group was treated with AP chemotherapy regimen,while the study group was treated with Bufei Xiaoji decoction on the basis of that of the control group.The clinical efficacy,the levels of tumor markers[cytokeratin 21-1 fragment(CYFRA21-1),carcinoembryonic antigen(CEA)],the scores of quality of life[Functional Assessment of Cancer Therapy-Lung cancer(FACT-L)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The disease control rate of the study group was 95.35%(41/43),which was higher than 79.01%(34/43)of the control group.After the treatment,the levels of CYFRA21-1 and CEA in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the FACT-L scores of the two groups were higher than those before the treatment,those of the study group were higher than the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Bufei Xiaoji decoction combined with AP chemotherapy regimen for the patients with advanced NSCLC can improve the disease control rate and the quality of life,reduce the levels of tumor markers,and has good safety.Moreover,it is superior to simple AP chemotherapy regimen.